(AOF) – Abionyx Pharma announces that it is the beneficiary of innovation aid of nearly 1 million euros from Bpifrance. The biotech specialist in innovative therapies based on the only natural recombinant apoA-I in the world specifies that this aid is intended to support the drug candidate CER-001 dedicated to the treatment of a severe indication in ophthalmology. This aid will be repayable at 0 rate on condition of success from the last quarter of 2026 until the first quarter of 2031.
© 2024 Agence Option Finance (AOF) – All reproduction rights reserved by AOF. AOF collects its data from the sources it considers the safest. However, the reader remains solely responsible for their interpretation and use of the information made available to them. The reader must therefore hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group
Did you like this article ? Share it with your friends using the buttons below.
